Bristol-Myers Squibb Company (BMY)

Executive Summary

Bristol-Myers Squibb is, at $58.48, the deepest-value large-cap pharma name we are tracking and one of the cleaner asymmetric setups in the broader U.S. health-care complex today. The stock trades at roughly 9.3 times consensus forward earnings, pays a 4.3 percent dividend yield supported by 17 consecutive years of dividend increases, and changes hands at a multiple that we believe already fully discounts the well-telegraphed Eliquis patent cliff while giving zero credit to a pipeline and recently-acquired-asset platform that we believe has the earnings power to backfill most or all of the lost Eliquis revenue by the early 2030s. What we are buying at $58 is the world’s largest oncology and immunology franchise outside of Pfizer and Merck.

What’s Inside The Full Report

• 15-year financial summary table — revenue, net income, GAAP & adjusted EPS
• Valuation framework — current multiples vs. 5-year historical range
• Peer comparison table — multiples, margins, balance-sheet metrics
• Base case, bull case, bear case price targets with explicit math
• Competitive position and economic moat analysis
• Management and capital allocation track record
• Balance sheet review — leverage, credit ratings, distribution coverage
• Insider activity — recent open-market buys / sells with interpretation
• Strategic acquisitions and divestitures history
• Sell-side consensus and where TTCM differs
• Detailed risk factors specific to the name
• Bull case and forward catalysts to watch
• TTCM rating with explicit ADD / TRIM price triggers